Sarepta Therapeutics annual shareholders’ equity
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Shareholders’ Equity Growth & History (SRPT)
Sarepta Therapeutics's shareholders’ equity was $1.14B for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.14B | −$387.1M | −25.34% |
| 2024 | 2024-12-31 | $1.53B | $668.4M | +77.78% |
| 2023 | 2023-12-31 | $859.3M | $474.4M | +123.23% |
| 2022 | 2022-12-31 | $384.9M | −$543.1M | −58.52% |
| 2021 | 2021-12-31 | $928.0M | $166.3M | +21.82% |
| 2020 | 2020-12-31 | $761.8M | −$56.4M | −6.90% |
| 2019 | 2019-12-31 | $818.2M | −$214.1M | −20.74% |
| 2018 | 2018-12-31 | $1.03B | $243.1M | +30.80% |
| 2017 | 2017-12-31 | $789.2M | $452.5M | +134.40% |
| 2016 | 2016-12-31 | $336.7M | $146.3M | +76.88% |
| 2015 | 2015-12-31 | $190.3M | −$57.3M | −23.14% |
| 2014 | 2014-12-31 | $247.7M | $461,000 | +0.19% |
| 2013 | 2013-12-31 | $247.2M | $123.5M | +99.87% |
| 2012 | 2012-12-31 | $123.7M | $92.7M | +298.75% |
| 2011 | 2011-12-31 | $31.0M | $33.8M | — |
| 2010 | 2010-12-31 | −$2.8M | −$26.4M | — |
| 2009 | 2009-12-31 | $23.6M | — | — |
Sarepta Therapeutics quarterly shareholders’ equity
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.53B | $123.0M | +8.76% |
| Q1 2026 | 2026-03-31 | $1.51B | $315.0M | +26.47% |
| Q4 2025 | 2025-12-31 | $1.14B | −$387.1M | −25.34% |
| Q3 2025 | 2025-09-30 | $1.32B | $99.0M | +8.11% |
| Q2 2025 | 2025-06-30 | $1.40B | $327.7M | +30.43% |
| Q1 2025 | 2025-03-31 | $1.19B | $228.9M | +23.82% |
| Q4 2024 | 2024-12-31 | $1.53B | $668.4M | +77.78% |
| Q3 2024 | 2024-09-30 | $1.22B | $456.7M | +59.75% |
| Q2 2024 | 2024-06-30 | $1.08B | $335.7M | +45.27% |
| Q1 2024 | 2024-03-31 | $961.2M | $248.4M | +34.86% |
| Q4 2023 | 2023-12-31 | $859.3M | $474.4M | +123.23% |
| Q3 2023 | 2023-09-30 | $764.4M | $333.5M | +77.41% |
| Q2 2023 | 2023-06-30 | $741.4M | $15.0M | +2.06% |
| Q1 2023 | 2023-03-31 | $712.7M | −$144.1M | −16.82% |
| Q4 2022 | 2022-12-31 | $384.9M | −$543.1M | −58.52% |
| Q3 2022 | 2022-09-30 | $430.8M | −$38.7M | −8.24% |
| Q2 2022 | 2022-06-30 | $726.5M | $241.3M | +49.75% |
| Q1 2022 | 2022-03-31 | $856.9M | $321.4M | +60.03% |
| Q4 2021 | 2021-12-31 | $928.0M | $166.3M | +21.82% |
| Q3 2021 | 2021-09-30 | $469.5M | −$422.5M | −47.37% |
| Q2 2021 | 2021-06-30 | $485.1M | −$557.8M | −53.48% |
| Q1 2021 | 2021-03-31 | $535.4M | −$609.4M | −53.23% |
| Q4 2020 | 2020-12-31 | $761.8M | −$56.4M | −6.90% |
| Q3 2020 | 2020-09-30 | $892.0M | −$103.2M | −10.37% |
| Q2 2020 | 2020-06-30 | $1.04B | −$56.3M | −5.12% |
| Q1 2020 | 2020-03-31 | $1.14B | −$203.7M | −15.11% |
| Q4 2019 | 2019-12-31 | $818.2M | −$214.1M | −20.74% |
| Q3 2019 | 2019-09-30 | $995.2M | $355.4M | +55.54% |
| Q2 2019 | 2019-06-30 | $1.10B | $400.1M | +57.24% |
| Q1 2019 | 2019-03-31 | $1.35B | $571.8M | +73.61% |
| Q4 2018 | 2018-12-31 | $1.03B | $243.1M | +30.80% |
| Q3 2018 | 2018-09-30 | $639.8M | −$57.3M | −8.22% |
| Q2 2018 | 2018-06-30 | $699.0M | $321.3M | +85.04% |
| Q1 2018 | 2018-03-31 | $776.8M | $347.6M | +81.00% |
| Q4 2017 | 2017-12-31 | $789.2M | $452.5M | +134.40% |
| Q3 2017 | 2017-09-30 | $697.2M | $288.5M | +70.61% |
| Q2 2017 | 2017-06-30 | $377.8M | $256.3M | +211.03% |
| Q1 2017 | 2017-03-31 | $429.1M | $290.2M | +208.82% |
| Q4 2016 | 2016-12-31 | $336.7M | $146.3M | +76.88% |
| Q3 2016 | 2016-09-30 | $408.6M | $285.4M | +231.58% |
| Q2 2016 | 2016-06-30 | $121.5M | −$43.9M | −26.56% |
| Q1 2016 | 2016-03-31 | $139.0M | −$61.8M | −30.78% |
| Q4 2015 | 2015-12-31 | $190.3M | −$57.3M | −23.14% |
| Q3 2015 | 2015-09-30 | $123.2M | −$163.0M | −56.94% |
| Q2 2015 | 2015-06-30 | $165.4M | −$134.5M | −44.86% |
| Q1 2015 | 2015-03-31 | $200.8M | −$28.2M | −12.32% |
| Q4 2014 | 2014-12-31 | $247.7M | $461,000 | +0.19% |
| Q3 2014 | 2014-09-30 | $286.2M | $39.2M | +15.88% |
| Q2 2014 | 2014-06-30 | $299.9M | $211.1M | +237.67% |
| Q1 2014 | 2014-03-31 | $229.0M | $141.7M | +162.33% |
| Q4 2013 | 2013-12-31 | $247.2M | $123.5M | +99.87% |
| Q3 2013 | 2013-09-30 | $247.0M | $251.6M | — |
| Q2 2013 | 2013-06-30 | $88.8M | $66.3M | +294.76% |
| Q1 2013 | 2013-03-31 | $87.3M | $73.3M | +522.46% |
| Q4 2012 | 2012-12-31 | $123.7M | $92.7M | +298.75% |
| Q3 2012 | 2012-09-30 | −$4.6M | −$36.3M | — |
| Q2 2012 | 2012-06-30 | $22.5M | −$12.6M | −35.99% |
| Q1 2012 | 2012-03-31 | $14.0M | — | — |
| Q4 2011 | 2011-12-31 | $31.0M | $33.8M | — |
| Q3 2011 | 2011-09-30 | $31.8M | — | — |
| Q2 2011 | 2011-06-30 | $35.1M | — | — |
| Q4 2010 | 2010-12-31 | −$2.8M | — | — |
Sarepta Therapeutics shareholders’ equity trends
Over the last five fiscal years, Sarepta Therapeutics's shareholders’ equity increased from $761.8M to $1.14B, a change of $378.9M. The latest reported quarter, Q2 2026, shows $1.53B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...